Publications

2025

Real world treatment patterns for recurrent and metastatic head and neck cancer in the post-KEYNOTE 048 era
Lee Daniel Y. , Pan Alexander , Yaskolko Maxim , Chiorazzi Michael , Bhatia Aarti , Burtness Barbara , Ishizuka Jeffrey J. Real world treatment patterns for recurrent and metastatic head and neck cancer in the post-KEYNOTE 048 era, Frontiers in Oncology,Volume 15 - 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1577509, DOI=10.3389/fonc.2025.1577509, ISSN=2234-943X
Peer-Reviewed Original Research
119 Reading vs Measuring: Comparison of Pathologist-Based Scores to Analytic Measurements
Bates K, Fernandez A, Martinez-Morilla S, Chan N, Benanto J, Reisenbichler E, Rimm D. 119 Reading vs Measuring: Comparison of Pathologist-Based Scores to Analytic Measurements. Laboratory Investigation 2025, 105: 102343. DOI: 10.1016/j.labinv.2024.102343.
Peer-Reviewed Original Research
542 Clinicopathologic Features of Thyroid Nodules with BRAF non-V600E Mutations
Verma A, Cedeño E, Abi-Raad R, Ladenheim A, Prasad M. 542 Clinicopathologic Features of Thyroid Nodules with BRAF non-V600E Mutations. Laboratory Investigation 2025, 105: 102772. DOI: 10.1016/j.labinv.2024.102772.
Peer-Reviewed Original Research
315 Clinicopathologic Characteristics of Thyroid Nodules with THADA-IGF2BP3 Fusion Identified on Fine Needle Aspiration
Bernhisel A, Sun T, Prasad M, Ladenheim A, Cai G, Adeniran A. 315 Clinicopathologic Characteristics of Thyroid Nodules with THADA-IGF2BP3 Fusion Identified on Fine Needle Aspiration. Laboratory Investigation 2025, 105: 102542. DOI: 10.1016/j.labinv.2024.102542.
Peer-Reviewed Original Research
411 Correlation of ACR-TI-RADS, Cytology, Histology, and Molecular studies
Yu S, Wang M, Langdon J, Sinard J, Cai G, Prasad M, Adeniran A. 411 Correlation of ACR-TI-RADS, Cytology, Histology, and Molecular studies. Laboratory Investigation 2025, 105: 102638. DOI: 10.1016/j.labinv.2024.102638.
Peer-Reviewed Original Research
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.
Machtay M, Torres-Saavedra P, Thorstad W, Nguyen-Tân P, Siu L, Holsinger F, El-Naggar A, Chung C, Cmelak A, Burtness B, Bednarz G, Quon H, Breen S, Gwede C, Dicker A, Yao M, Jordan R, Dorth J, Lee N, Chan J, Dunlap N, Bar-Ad V, Stokes W, Chakravarti A, Sher D, Rao S, Harris J, Yom S, Le Q, Bar-Ad V, Bednarz G, Bowles D, Breen S, Burtness B, Chakravarti A, Chan J, Chung C, Cmelak A, Dicker A, Dorth J, Dunlap N, El-Naggar A, Gwede C, Harris J, Holsinger F, Jones C, Jordan R, Krempl G, Le Q, Lee N, Lominska C, Ma D, Machtay M, Mell L, Nguyen-Tan P, Quon H, Raben A, Rao S, Samuels S, Sher D, Siu L, Spencer S, Stokes W, Takiar V, Thorstad W, Torres-Saavedra P, Wilke C, Yao M, Yom S, Young M. Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer. Journal Of Clinical Oncology 2025, jco2401829. PMID: 39841939, DOI: 10.1200/jco-24-01829.
Peer-Reviewed Original Research
Concepts
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
Lopez de Rodas M, Villalba-Esparza M, Sanmamed M, Chen L, Rimm D, Schalper K. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nature Reviews Clinical Oncology 2025, 22: 163-181. PMID: 39820025, DOI: 10.1038/s41571-024-00984-x.
Peer-Reviewed Original Research
MeSH Keywords and Concepts
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing
Taube J, Sunshine J, Angelo M, Akturk G, Eminizer M, Engle L, Ferreira C, Gnjatic S, Green B, Greenbaum S, Greenwald N, Hedvat C, Hollmann T, Jiménez-Sánchez D, Korski K, Lako A, Parra E, Rebelatto M, Rimm D, Rodig S, Rodriguez-Canales J, Roskes J, Schalper K, Schenck E, Steele K, Surace M, Szalay A, Tetzlaff M, Wistuba I, Yearley J, Bifulco C. Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing. Journal For ImmunoTherapy Of Cancer 2025, 13: e008875. PMID: 39779210, PMCID: PMC11749220, DOI: 10.1136/jitc-2024-008875.
Peer-Reviewed Original Research
MeSH Keywords and Concepts

2024

See All Publications

Publications

2025

Real world treatment patterns for recurrent and metastatic head and neck cancer in the post-KEYNOTE 048 era

119 Reading vs Measuring: Comparison of Pathologist-Based Scores to Analytic Measurements

542 Clinicopathologic Features of Thyroid Nodules with BRAF non-V600E Mutations

315 Clinicopathologic Characteristics of Thyroid Nodules with THADA-IGF2BP3 Fusion Identified on Fine Needle Aspiration

411 Correlation of ACR-TI-RADS, Cytology, Histology, and Molecular studies

Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.

Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach

Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing

2024

Racial Disparities in Perioperative Outcomes for Patients With Head and Neck Cancer

The widespread application of trans-oral robotic surgery in HPV-related head and neck cancer: one size does not fit all

215P Differential spatial gene expression and clinicopathologic characteristics are associated with exceptional response to immune checkpoint inhibition in recurrent/metastatic head and neck cancer

The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably?

Financial Compensation of Academic Otolaryngologists in the United States: Trends and Distribution

109 Development of a novel immuno-metabolic spatial signature to predict response and resistance to immunotherapy in NSCLC patients

127 Digital pathology prognostic biomarkers- time for clinical application in melanoma

649 A phase 1 dose-escalation and expansion study of CUE-101 as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer

Absence of the dolichol synthesis gene DHRSX leads to N-glycosylation defects in Lec5 and Lec9 Chinese hamster ovary cells

Evaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma

EIF1AX mutation in thyroid nodules: a histopathologic analysis of 56 cases in the context of institutional practices

850MO Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN cancer research group (EA3163)

690TiP HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors

907P Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

945TiP JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)

BCAM (basal cell adhesion molecule) protein expression in different tumor populations

Laryngeal rare benign non-epithelial tumors and sarcomas emphasizing on chondrosarcomas: A literature review and a case presentation